These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 8209972)

  • 1. [Verification of desferrioxamine ototoxicity by high-frequency audiometry in patients undergoing dialysis].
    Martín C; Lens XM; Prieto A; Alonso R; Correa B; Arcocha V; Soto A
    An Otorrinolaringol Ibero Am; 1994; 21(2):193-8. PubMed ID: 8209972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desferrioxamine ototoxicity in an adult transfusion-dependent population.
    Chiodo AA; Alberti PW; Sher GD; Francombe WH; Tyler B
    J Otolaryngol; 1997 Apr; 26(2):116-22. PubMed ID: 9106087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.
    D'Haese PC; Couttenye MM; Goodman WG; Lemoniatou E; Digenis P; Sotornik I; Fagalde A; Barsoum RS; Lamberts LV; De Broe ME
    Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of various treatment modalities on aluminium associated bone disease.
    Ihle BU; Buchanan MR; Stevens B; Becker GJ; Kincaid-Smith P
    Proc Eur Dial Transplant Assoc; 1983; 19():195-202. PubMed ID: 6348735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of desferrioxamine on aluminum kinetics during hemodialysis.
    Stummvoll HK; Graf H; Meisinger V
    Miner Electrolyte Metab; 1984; 10(4):263-6. PubMed ID: 6749073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ototoxicity of desferrioxamine in hemodialyzed patients].
    Sabater F; Cases A; Deola MD; López-Pedret J; Traserra J; Revert L
    Acta Otorrinolaringol Esp; 1989; 40(1):13-6. PubMed ID: 2629920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U
    Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of aluminium intoxication: a new scheme for desferrioxamine administration.
    Douthat WG; Acuña Aguerre G; Fernández Martín JL; Mouzo R; Cannata Andía JB
    Nephrol Dial Transplant; 1994; 9(10):1431-4. PubMed ID: 7816256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy.
    Milne FJ; Sharf B; Bell P; Meyers AM
    Clin Nephrol; 1983 Oct; 20(4):202-7. PubMed ID: 6641027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid conversion from aluminium bone disease to hyperparathyroid bone disease by desferrioxamine.
    Terao N; Suzuki M; Homma S; Asano Y; Hosoda S; Furuse M
    Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1129-33. PubMed ID: 3216555
    [No Abstract]   [Full Text] [Related]  

  • 12. [The deferoxamine loading test as a non-invasive method for diagnosing Al-related bone disease in hemodialysis patients; efficacy of deferoxamine therapy for the disease].
    Umetani N; Sato N; Yoshida A; Marumo F
    Nihon Jinzo Gakkai Shi; 1988 Feb; 30(2):143-50. PubMed ID: 3386018
    [No Abstract]   [Full Text] [Related]  

  • 13. Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease.
    Marumo F; Umetani N; Sato N; Takahashi Y
    J UOEH; 1987 Mar; 9 Suppl():140-52. PubMed ID: 3602745
    [No Abstract]   [Full Text] [Related]  

  • 14. [Evaluation of desferrioxamine ototoxicity in thalassemic patients. Follow-up over a 5-year period and results].
    Sacco M; Meleleo D; Tricarico N; Greco Miani A; Serra E; Parlatore L
    Minerva Pediatr; 1994 May; 46(5):225-30. PubMed ID: 8090141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
    Graf H; Stummvoll HK; Meisinger V
    Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
    Lillevang ST; Pedersen FB
    Nephrol Dial Transplant; 1989; 4(7):676. PubMed ID: 2510071
    [No Abstract]   [Full Text] [Related]  

  • 17. Kinetics of aluminium removal by desferrioxamine VIA hemodialysis in a case with aluminium bone disease.
    Terao N; Sizuki M; Ando Y; Kato K; Asano Y; Hosoda S; Suka T
    Nihon Jinzo Gakkai Shi; 1985 Sep; 27(9):1305-12. PubMed ID: 4087551
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of a desferrioxamine "microdose" to chelate aluminum in hemodialysis patients.
    Jorge C; Gil C; Possante M; Catarino MC; Cruz A; Andrade R; Teixeira R; Santos N; Ferreira A
    Clin Nephrol; 1999 Nov; 52(5):335-6. PubMed ID: 10585000
    [No Abstract]   [Full Text] [Related]  

  • 19. [Osteomalacia induced by aluminum in a patient under chronic hemodialysis: successful treatment with desferrioxamine].
    Espinoza O; Gehrung E; Roessler E; Katz E; Pérez A; Delmastro J
    Rev Med Chil; 1986 Sep; 114(9):867-71. PubMed ID: 3575972
    [No Abstract]   [Full Text] [Related]  

  • 20. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
    Ciancioni C; Poignet JL; Mauras Y; Panthier G; Delons S; Allain P; Man NK
    Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.